TP53 and neoplasm: Specifically, in ERα66-negative cells (UM-SCC-11A), 24R,25-(OH)2D3 inhibits cellular proliferation and triggers apoptosis through the activation of the p53/p21 pathway (17, 19), whereas in ERα66-positive cells (UM-SCC-12), the same metabolite promotes tumor progression (19).